Many companies in the pharmaceutical industry experience dynamic movements up and down the charts when test results are released to the public. Aeolus Pharmaceuticals Inc. (OTCBB: AOLS) scored an A-plus today with their news about AEOL 10113, demonstrating potential to accelerate recovery of bone marrow stem cells following cancer radiation therapy. Shares were trading well above the 52-week high of 91 cents to $1.10 (up 38 percent) on volume of over 372 thousand shares.
In a press release, Aeolus announced the presentation of data by researchers at Loma Linda University Medical Center, National Jewish Medical and Research Center and Duke University showing that one of the company’s metalloporphyrin antioxidants, AEOL 10113, demonstrated protection of healthy normal cells in mice with prostate tumor cells treated with radiation therapy. The study also showed the compound did not interfere with the tumor destruction effects of the radiation therapy.
Aeolus also announced in a press release yesterday that AEOL 10113 demonstrated protection of healthy normal cells in mice with prostate tumor cells treated with radiation therapy. The study also showed that the compound did not interfere with the tumor destruction effects of the radiation therapy.
Lots of good news and a steady climb up the charts are exactly what investors like to see. The company has risen from the depths of a 40 cent share price to their current $1.00 plus range in the past 3 months.
Aelous is a biopharmaceutical company that develops catalytic antioxidant compounds for diseases and disorders of the central nervous system, respiratory system, autoimmune system and oncology.